

Steps taken for prequalification

I BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Emcure Pharmaceuticals Limited submitted in 2018 an application for [HA701 trade name]¹ to be assessed with the aim of including [HA701 trade name] in the list of prequalified medicinal products for the treatment of HIV/AIDS.

[HA701 trade name] was assessed according to the ‘Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

Sept 2017	The manufacturer of the API was inspected for compliance with WHO requirements for GMP.
Oct 2017	The sites relevant for the bioequivalence study were inspected for compliance with WHO requirements for GLP and GCP.
March 2018	During the meeting of the assessment team the safety and efficacy data were reviewed and further information was requested.
April 2018	The applicant’s response letter was received.
May 2018	The safety and efficacy data were reviewed and found to comply with the relevant WHO requirements.
March and May 2018	During the meetings of the assessment team the quality data were reviewed and further information was requested.
Sept 2018	The applicant’s response letter was received.
Sept 2018	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Nov 2018	The applicant’s response letter was received.
Nov 2018	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Dec 2018	The applicant’s response letter was received.
Jan 2019	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Feb 2019	The manufacturer of the FPP was inspected for compliance with WHO requirements for GMP.
Feb 2019	The applicant’s response letter was received.
March 2019	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
April 2019	The applicant’s response letter was received.
May 2019	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
July 2019	In between the meetings of the assessment team the applicant’s response letter was received. The additional quality data were reviewed and further information was requested.
Aug 2019	The applicant’s response letter was received.
Jan 2020	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
Jan 2020	The applicant’s response letter was received.
Feb 2020	The additional quality data were reviewed and further information was requested.
Feb 2020	The applicant’s response letter was received.

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s responsibility.

Feb 2020	The quality data were reviewed and found to comply with the relevant WHO requirements.
Feb 2020	Product dossier accepted (quality assurance).
03 March 2020	[HA701 trade name] was included in the list of prequalified medicinal products.

II GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer, Commitments and Inspection status

Manufacturer of the finished product and responsible for batch release

Emcure Pharmaceuticals Ltd
Plot No. P-1 & P-2, ITBT Park
Phase II, MIDC
Hinjewadi, Pune
Maharashtra 411057
India

Commitments for Prequalification

None which has an impact on the benefit-risk profile of the medicinal product.

Inspection status

The sites inspected were found to be in compliance with WHO requirements for GMP, GLP and GCP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

<https://extranet.who.int/prequal/>